How long does resistance to Mobotinib last?

Mobocertinib (Mobocertinib) is a third-generation EGFRtyrosine kinase inhibitor (TKI), specifically Targeted at EGFRexon20 patients with non-small cell lung cancer (NSCLC) insertion mutations. Althoughmobosetinibhas shown significant efficacy in slowing disease progression and improving patient outcomes, the emergence of drug resistance remains an important issue. According to clinical data and research, most patients develop drug resistance, manifested by disease progression, approximately 10 to 14 months after treatment.

The emergence of drug resistance is often related to genetic mutations that occur in cancer cells during treatment. For mobocertinib, resistance mechanisms may include secondary mutations in the EGFR gene, rendering the drug no longer able to effectively bind to and inhibit tyrosine kinase activity. In addition, cancer cells may evade the inhibitory effects of Mobotinib by activating other signaling pathways (e.g. MET amplification) or changing their phenotype (e.g. epithelial - mesenchymal transition, EMT).

To deal with resistance to mobotinib , researchers and clinicians have proposed a variety of strategies. Combination therapy is a potential approach that could delay the emergence of resistance and improve treatment effectiveness by combining mobocertinib with other targeted or immunotherapy drugs. In addition, after drug resistance occurs, doctors can choose other second-line or third-line treatment options based on the specific resistance mechanism, such as different TKI drugs or chemotherapy regimens targeting EGFRsecondary mutations.

Participation in clinical trials is also an important way to deal with drug resistance. Clinical trials provide patients with the opportunity to explore new drugs and new treatment combinations that may lead to better treatment outcomes and survival. During the treatment process, patients should work closely with their doctors, monitor their condition regularly, and adjust treatment plans in a timely manner to cope with the emergence of drug resistance.